专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明公开

EP1837398A1 DRUGS FOR DISEASES ACCOMPANYING CHANGES IN TOTAL BILE ACID POOL OR LIPID METABOLISM DISORDERS AND METHOD OF SCREENING THESE DRUGS 审中-公开
标题翻译：药制剂因更改THROUGHOUT胆酸QUANTITY相关疾病和脂质代谢和方法失常搜索该原料药
公开(公告)号：EP1837398A1
公开(公告)日：2007-09-26
申请号：EP05842245.2
申请日：2005-12-26
申请人： BANYU PHARMACEUTICAL CO., LTD.
发明人： MARUYAMA, Takaharu , TANAKA, Kenichi , TAMAI, Yoshitaka , SUZUKI, Jun
IPC分类号： C12N15/09 , G01N33/68 , C12Q1/02 , C12Q1/68 , A01K67/027 , A61K31/7088 , A61K45/00 , A61K48/00 , A61P1/16 , C12N15/10 , G01N33/15
CPC分类号： A61K31/7008 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , C07K14/723 , C12N15/1086 , G01N33/5038 , G01N33/5088 , G01N33/92 , G01N2500/00 , G01N2800/044 , G01N2800/08
摘要： A Gpbar1-deficient mouse is constructed and it is examined whether or not Gpbar1 participates in the regulation of bile acid homeostasis and lipid metabolism. As a result, the total bile acid pool is decreased in the Gpbar1-deficient mouse without showing any change in the fecal bile acid level. A female Gpbar1-deficient mouse having been fed with a high fat feed shows a significant increase in body weight compared with a wild type mouse, which is caused by an increase in fat. These facts suggest that Gpbar1 contributes to the regulation of bile acid homeostasis and lipid metabolism.
摘要翻译：甲GPBAR1缺陷小鼠被构造和它检查是否GPBAR1参与胆汁酸内环境稳定和脂类代谢的调控。其结果是，总的胆汁酸池减少在GPBAR1缺陷小鼠没有显示出在粪便胆汁酸水平的任何变化。已供给的阴GPBAR1缺陷小鼠用高脂肪饲料示出体重显著增加与野生型小鼠相比，所有这些是由以脂肪增加。这些事实表明没有GPBAR1：促进胆汁酸的动态平衡和脂质代谢的调控。

42. 发明公开

EP1774329A2 INTERLEUKIN-8 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF 审中-公开
标题翻译：白细胞介素8同源的多肽及其治疗用途
公开(公告)号：EP1774329A2
公开(公告)日：2007-04-18
申请号：EP05770110.4
申请日：2005-07-07
申请人： Genentech, Inc.
发明人： EATON, Dan, L. , PISABARRO, Maria, Teresa , SCHMIDT, Kerstin, N. , VANDLEN, Richard , CHIANG, Nancy , DIEHL, Lauri
IPC分类号： G01N33/53 , A61K39/395 , C12N5/06 , C07K16/44 , C07K16/18
CPC分类号： G01N33/57449 , C07K14/5421 , C07K16/24 , C07K2317/76 , G01N33/57415 , G01N33/57442 , G01N33/57496 , G01N33/576 , G01N33/6869 , G01N2333/715 , G01N2800/08 , G01N2800/085 , G01N2800/24

43. 发明公开

EP1751550A2 LIVER DISEASE DIAGNOSIS SYSTEM, METHOD AND GRAPHICAL USER INTERFACE 有权转让
标题翻译：系统，方法和图形用户界面，用于诊断肝病
公开(公告)号：EP1751550A2
公开(公告)日：2007-02-14
申请号：EP05736052.1
申请日：2005-04-14
申请人： Edda Technology, Inc.
发明人： WEI, Guo-Qing , QIAN, Jian-Zhong , FAN, Li , LIANG, Cheng-Chung
IPC分类号： G01N33/53
CPC分类号： A61B6/566 , A61B6/463 , A61B6/465 , A61B6/50 , A61B6/504 , A61B6/5235 , A61B6/5247 , G01N2800/08 , G06F19/321 , G06T2207/30056 , G16H40/63
摘要： System and graphical user interfaces are disclosed for liver disease diagnosis. A visual data manipulation page is used for manipulating one or more liver visual data sets, retrieved together with non-visual information associated with a subject and specific to a liver disease. The visual data manipulation page includes a first area for manipulating the one or more data sets and a second area for providing a plurality of selectable means to activate one or more data manipulation operations to be performed with respect to the one or more data sets displayed in the first area. When the first area is configured to manipulate more than one data set, each image is from a corresponding data set and images from different data sets can be displayed synchronously.

44. 发明公开

EP1601683A2 NOVEL NON-INVASIVE MARKER FOR LIVER DISEASE 有权
标题翻译：新的非侵入MARKER肝病
公开(公告)号：EP1601683A2
公开(公告)日：2005-12-07
申请号：EP04720548.9
申请日：2004-03-14
申请人： Ramot at Tel Aviv University Ltd.
发明人： LEDERKREMER, Gerardo Z. , KONDRATYEV, Maria
IPC分类号： C07K1/00
CPC分类号： C07K16/28 , C07K16/303 , C07K2317/34 , G01N33/57438 , G01N33/6893 , G01N2333/705 , G01N2800/08 , G01N2800/56
摘要： A monoclonal antibody or fragment thereof, capable of specifically binding to at least one epitope of sH2a and/or being elicited by at least one epitope, and assays, kits, and methods of use thereof.

45. 发明公开

EP3310901A1 IN VITRO PRODUCTION OF CHOLANGIOCYTES 有权
标题翻译：体外生产胆管细胞
公开(公告)号：EP3310901A1
公开(公告)日：2018-04-25
申请号：EP16732328.6
申请日：2016-06-21
申请人： Cambridge Enterprise Limited
发明人： VALLIER, Ludovic , SAMPAZIOTIS, Fotis , HANNAN, Nicholas
IPC分类号： C12N5/071 , A61K35/413 , G01N33/50
CPC分类号： C12N5/0672 , A61K35/413 , A61P1/16 , C12N5/067 , C12N5/0676 , C12N5/0679 , C12N2501/11 , C12N2501/115 , C12N2501/119 , C12N2501/15 , C12N2501/155 , C12N2501/16 , C12N2501/36 , C12N2501/385 , C12N2501/415 , C12N2501/42 , C12N2501/999 , C12N2503/02 , C12N2506/14 , C12N2506/22 , C12N2506/45 , C12N2513/00 , C12N2533/90 , G01N33/5008 , G01N33/5044 , G01N33/5091 , G01N2800/08
摘要： This invention relates to the efficient generation of cholangiocyte progenitor (CP) cells. Foregut stem cells (FSCs) are cultured in a hepatic induction medium comprising bone morphogenetic protein (BMP) and a TGFβ signalling inhibitor to produce a population of hepatoblasts. The hepatoblasts are then cultured in a biliary induction medium comprising fibroblast growth factor (FGF), retinoic acid and a TGFβ ligand to produce a population of cholangiocyte progenitors (CPs). The cholangiocyte progenitors (CPs) may be matured into cholangiocyte-like cells (CLCs) that display functional properties of Common Bile Duct (CBD) cholangiocytes. Methods, kits, cell populations and uses of these cell populations are provided.

46. 发明公开

EP3129787A1 PROGNOSTIC TESTS FOR HEPATIC DISORDERS 有权转让
标题翻译： PROGNOSTISCHE测试FÜRLEBERSTÖRUNGEN
公开(公告)号：EP3129787A1
公开(公告)日：2017-02-15
申请号：EP15713925.4
申请日：2015-04-08
申请人： Centre Hospitalier Universitaire D'angers , Université d'Angers
发明人： CALÈS, Paul , BOURSIER, Jérôme , BERTRAIS, Sandrine
IPC分类号： G01N33/576 , G01N33/68
CPC分类号： G06F19/3437 , G01N33/576 , G01N33/6893 , G01N2800/08 , G06F17/18 , G06F19/00 , G06F19/3431 , G16H50/30 , G16H50/50
摘要： The present invention relates to in vitro prognostic method for assessing the risk of death or of liver-related event in a subject, comprising: a. obtaining at least one, preferably at least 2, of the following variables from the subject: i. biomarkers measured in a sample from the subject; ii. clinical data; iii. binary markers; iv. blood test results; b. optionally obtaining at least one blood test result by univariate combination, preferably with a binary logistic regression, of the at least one variable obtained in step (a), said blood test not being a Fibrotest, c. obtaining at least one physical data from medical imaging or clinical measurement, preferably from elastometry, more preferably from Vibration Controlled Transient Elastography (VCTE), and d. mathematically combining in a multivariate time-dependent model - said at least one variable obtained in step (a) and/or said at least one blood test result obtained in step b); and - said at least one physical data, obtained in step (c) thereby obtaining a prognostic score.
摘要翻译：本发明涉及用于评估受试者的死亡风险或肝脏相关事件的体外预后方法，包括：a。从主题中获得至少一个，优选至少2个以下变量：i。在受试者样本中测量的生物标志物; II。临床资料; III。二进制标记 IV。血液检查结果; 湾任选地通过单因素组合（优选用二元逻辑回归）获得至少一个在步骤（a）中获得的至少一个变量的血液测试结果，所述血液测试不是Fibrotest，c。从医学成像或临床测量获得至少一个物理数据，优选地来自弹性测量，更优选地来自振动控制瞬态弹性成像（VCTE），以及d。在多变量时间依赖模型中数学组合 - 所述步骤（a）中获得的至少一个变量和/或步骤b）中获得的所述至少一个血液测试结果; 和 - 在步骤（c）中获得的至少一个物理数据，由此获得预后评分。

47. 发明公开

EP2938740A4 METHODS FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES 有权转让
标题翻译：方法的GALLENSÄUREHOMÖOSTASE的调节和治疗瘿酸病杂志
公开(公告)号：EP2938740A4
公开(公告)日：2016-11-30
申请号：EP13868063
申请日：2013-12-26
申请人： NGM BIOPHARMACEUTICALS INC
发明人： LING LEI , LUO JIAN
IPC分类号： C12P21/02 , C07K14/50
CPC分类号： A61K38/1825 , C07K14/50 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/92 , G01N2500/04 , G01N2800/04 , G01N2800/08
摘要： The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

48. 发明公开

EP2983693A4 Sept4/ARTS AS A TUMOR SUPPRESSOR IN THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF HEPATIC DISORDERS 审中-公开
标题翻译： SEPT4 / ARTS作为肿瘤抑制诊断，预后和治疗肝脏疾病的
公开(公告)号：EP2983693A4
公开(公告)日：2016-10-26
申请号：EP14782569
申请日：2014-04-07
申请人： UNIV CARMEL HAIFA ECONOMIC COR , UNIV ROCKEFELLER
发明人： LARISCH SARIT , STELLER HERMANN
IPC分类号： A61K38/17 , A61P1/16 , A61P35/00 , C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , A61K31/185 , A61K31/53 , A61K38/17 , C12Q2600/118 , C12Q2600/154 , G01N33/57438 , G01N33/576 , G01N2800/08 , G01N2800/085 , G01N2800/52 , G01N2800/54
摘要： The invention relates to methods for the diagnosis and prognosis of hepatic disorder and associated pathologies as well as of a solid proliferative disorder in a mammalian subject. More specifically, the methods of the invention are based on determining the expression, methylation of ARTS as well as histone trimethylation. The invention further provides therapeutic methods for treating said disorders.

49. 发明公开

EP2930515A1 Prognostic tests for hepatic disorders 审中-公开
标题翻译：预测测试费尔伯斯特伦根
公开(公告)号：EP2930515A1
公开(公告)日：2015-10-14
申请号：EP14163948.4
申请日：2014-04-08
申请人： UNIVERSITE D'ANGERS , Centre Hospitalier Universitaire d'Angers
发明人： Calès, Paul , Boursier, Jérôme , Bertrais, Sandrine
IPC分类号： G01N33/576 , G01N33/68
CPC分类号： G06F19/3437 , G01N33/576 , G01N33/6893 , G01N2800/08 , G06F17/18 , G06F19/00 , G06F19/3431 , G16H50/30 , G16H50/50
摘要： The present invention relates to in vitro prognostic method for assessing the risk of death or of liver-related event in a subject, comprising:
a. obtaining at least one, preferably at least 2, of the following variables from the subject:
i. biomarkers measured in a sample from the subject;
ii. clinical data;
iii. binary markers;
iv. blood test results;

b. optionally obtaining at least one blood test result by univariate combination, preferably with a binary logistic regression, of the at least one variable obtained in step (a), said blood test not being a Fibrotest,
c. obtaining at least one physical data from medical imaging or clinical measurement, preferably from elastometry, more preferably from Vibration Controlled Transient Elastography (VCTE), and
d. mathematically combining in a multivariate time-dependent model
- said at least one variable obtained in step (a) and/or said at least one blood test result obtained in step b); and
- said at least one physical data, obtained in step (c)

thereby obtaining a prognostic score.
摘要翻译：本发明涉及用于评估受试者的死亡风险或肝脏相关事件的体外预后方法，包括：a。从主题中获得至少一个，优选至少2个以下变量：i。在受试者样本中测量的生物标志物; II。临床资料; III。二进制标记 IV。血液检查结果; 湾任选地通过单因素组合（优选用二元逻辑回归）获得至少一个在步骤（a）中获得的至少一个变量的血液测试结果，所述血液测试不是Fibrotest，c。从医学成像或临床测量获得至少一个物理数据，优选地来自弹性测量，更优选地来自振动控制瞬态弹性成像（VCTE），以及d。在多变量时间依赖模型中数学组合 - 所述步骤（a）中获得的至少一个变量和/或步骤b）中获得的所述至少一个血液测试结果; 和 - 在步骤（c）中获得的至少一个物理数据，由此获得预后评分。

50. 发明公开

EP2923202A1 BIOMARKERS FOR THE IDENTIFICATION OF LIVER DAMAGE 审中-公开
标题翻译：生物识别器ZEN IDENTIFIZIERUNG VONLEBERSCHÄDEN
公开(公告)号：EP2923202A1
公开(公告)日：2015-09-30
申请号：EP13786591.1
申请日：2013-10-24
申请人： THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY d/b/a CAROLINAS HEALTHCARE SYSTEM
发明人： BONKOVSKY, Herbert L , FOUREAU, David , NORTON, H. James , STEUERWALK, Nury
IPC分类号： G01N33/50
CPC分类号： G01N33/6893 , G01N2333/49 , G01N2333/503 , G01N2333/523 , G01N2333/525 , G01N2333/54 , G01N2333/5406 , G01N2333/5409 , G01N2333/5412 , G01N2333/5425 , G01N2333/5434 , G01N2333/5437 , G01N2333/765 , G01N2800/08 , G01N2800/085 , G01N2800/52 , G01N2800/60
摘要： Methods and kits for characterizing liver damage in an individual are provided. The methods employ the use of immune analytes as biomarkers for detecting liver damage and predicting the likelihood that an individual suffering from liver damage will experience life-threatening liver failure. Concentration values for serum albumin and other identified immune analytes are obtained or determined from a blood sample taken from the individual. The obtained concentration values are then compared to corresponding concentrations from individuals having a healthy liver. By comparing the concentrations, an individual's likelihood of developing life-threatening liver failure and needing a liver transplant within a given time period (e.g., 6 months) can be identified.
摘要翻译：提供了用于表征个体肝损伤的方法和试剂盒。该方法采用免疫分析物作为检测肝损伤的生物标志物，并预测患有肝损伤的个体将会遇到危及生命的肝衰竭的可能性。从取自个体的血液样品获得或确定血清白蛋白和其他鉴定的免疫分析物的浓度值。然后将获得的浓度值与具有健康肝脏的个体的相应浓度进行比较。通过比较浓度，可以确定个体在给定时间段（例如6个月）内发展危及生命的肝衰竭和需要肝移植的可能性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式